A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506871-88-00

Acronym

M22-947

Enrollment

196

Registered

2024-01-10

Start date

2022-10-07

Completion date

Unknown

Last updated

2025-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026